RPG Investment Advisory’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-56,425
Closed -$7.64M 89
2021
Q4
$7.64M Sell
56,425
-180
-0.3% -$21.3K 1.19% 37
2021
Q3
$6.11M Buy
56,605
+6,728
+13% +$769K 1.01% 54
2021
Q2
$5.62M Buy
49,877
+419
+0.8% +$47.2K 0.92% 62
2021
Q1
$5.35M Sell
49,458
-24,311
-33% -$2.6M 0.96% 58
2020
Q4
$7.9M Buy
73,769
+62
+0.1% +$5.96K 1.59% 22
2020
Q3
$6.46M Buy
73,707
+81
+0.1% +$7.63K 1.58% 20
2020
Q2
$7.23M Sell
73,626
-755
-1% -$66.5K 1.91% 18
2020
Q1
$5.67M Buy
74,381
+1,230
+2% +$105K 1.6% 21
2019
Q4
$6.48M Sell
73,151
-23,500
-24% -$1.95M 1.48% 22
2019
Q3
$7.32M Buy
96,651
+19,373
+25% +$1.33M 1.74% 13
2019
Q2
$5.63M Buy
77,278
+2,296
+3% +$180K 1.33% 33
2019
Q1
$6.04M Buy
74,982
+70,580
+1,603% +$5.77M 1.41% 31
2018
Q4
$406K Hold
4,402
0.1% 93
2018
Q3
$416K Sell
4,402
-418
-9% -$39.6K 0.09% 93
2018
Q2
$446K Buy
4,820
+177
+4% +$17.3K 0.1% 96
2018
Q1
$440K Hold
4,643
0.1% 99
2017
Q4
$449K Sell
4,643
-100
-2% -$9.43K 0.11% 95
2017
Q3
$421K Buy
4,743
+33
+0.7% +$2.51K 0.11% 98
2017
Q2
$342K Buy
4,710
+1,580
+50% +$106K 0.09% 98
2017
Q1
$203K Buy
+3,130
New +$197K 0.06% 113

Other funds holding ABBV

RPG Investment Advisory's ABBV Position: Q1 2022 in Review

RPG Investment Advisory sold out of AbbVie (ABBV) in Q1 2022, closing a stake of 56,425 shares — an estimated $7.64M sold.

RPG Investment Advisory first reported a position in ABBV in Q1 2017 and held it in 20 quarters. The position peaked at $7.9M in Q4 2020. 3,052 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

  • RPG Investment Advisory reported no remaining AbbVie position as of Q1 2022 after selling out during the quarter.
  • RPG Investment Advisory sold 56,425 AbbVie shares in Q1 2022, an estimated $7.64M.
  • RPG Investment Advisory first reported a position in AbbVie in Q1 2017 and held it in 20 quarters.
  • RPG Investment Advisory's AbbVie position peaked at $7.9M in Q4 2020.
  • 3,052 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on RPG Investment Advisory's 13F filing for Q1 2022, filed 10 May 2022.